The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics
Muh Geot Wong(FIND), Michelle Hladunewich(Sunnybrook Health Science Centre), Ming‐Hui Zhao(China National Petroleum Corporation (China)), Laurent Billot(The George Institute for Global Health), Helen Monaghan(The George Institute for Global Health), Giuseppe Remuzzi(Mario Negri Institute for Pharmacological Research), Alan Cass(University of Sydney), Vlado Perkovic(New South Wales Department of Health), Vivekanand Jha(The George Institute for Global Health), Mark Woodward(UNSW Sydney), David W. Johnson(Hennepin County), Adeera Levin(University of British Columbia), Heather N. Reich(University Health Network), John Feehally(University of Leicester), Tak Mao Chan(Chinese University of Hong Kong), David C. Wheeler(University College London), Jicheng Lv(Ministry of Education of the People's Republic of China), Richard J. Glassock(University of California, Los Angeles), Rajiv Agarwal(Richard L. Roudebush VA Medical Center), Zhihong Liu(Chinese Academy of Sciences), Hong Zhang(Peking University), Meg Jardine(Royal North Shore Hospital), Jürgen Floege(Westfälische Hochschule), Yangfeng Wu(Peking University), Daniel C. Cattran(Toronto Rehabilitation Institute), Lai Seong Hooi(Sultanah Aminah Hospital), Sean Barbour
Cited by 32
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k